GlassScriptPhysician profile
Kathi S Gardner
NPI 1689017972
$7,473.59
in general payments reported to CMS, 2019-2025
60 companies · $1,306 in 2025
The $1,306 reported for 2025 was more than what 95% of General Practice (Registered Nurse) providers received nationally (typical 2025 total: $110).
See the full distribution for General Practice (Registered Nurse)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,574 · 2022: $1,704 · 2023: $952 · 2024: $1,937 · 2025: $1,306.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,787 · Education: $408.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,786.75 |
| Education | $408.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $693.18 | 2021-2025 | Trodelvy |
| Amgen INC. | $608.87 | 2021-2023 | Lumakras |
| Astellas Pharma US INC | $407.68 | 2022-2024 | Vyloy, Xtandi, Xospata |
| Genentech USA, INC. | $394.92 | 2021-2025 | Venclexta, Phesgo, Polivy |
| E.R. Squibb & Sons, L.L.C. | $383.87 | 2022-2025 | Opdivo, Reblozyl |
| Novartis Pharmaceuticals Corporation | $277.82 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $264.13 | 2021-2025 | Fruzaqla, Ninlaro, Iclusig |
| Astrazeneca Pharmaceuticals LP | $250.58 | 2022-2025 | Imfinzi, Lynparza, Enhertu |
| Seagen INC. | $248.05 | 2021-2023 | Adcetris, Padcev |
| Celgene Corporation | $223.43 | 2023-2025 | Reblozyl |
| Genzyme Corporation | $219.93 | 2021-2025 | |
| Sanofi-Aventis U.S. LLC | $218.99 | 2021-2022 | |
| Kite Pharma, INC. | $207.29 | 2021-2023 | Yescarta |
| Lilly USA, LLC | $187.63 | 2021-2025 | Verzenio, Jaypirca |
| Abbvie INC. | $186.91 | 2022-2024 |
Show all 60 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kathi Gardner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.